Business Description
Palvella Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US6979471090
Total Employee Number:
29Compare
Compare
Traded in other countries / regions
PVLA.USAPI6.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2024-12-16Description
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 468.38 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -25.7 | |||||
3-Year EPS without NRI Growth Rate | -14.6 | |||||
3-Year FCF Growth Rate | -18.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.19 | |||||
9-Day RSI | 49.33 | |||||
14-Day RSI | 51.32 | |||||
3-1 Month Momentum % | 51.16 | |||||
6-1 Month Momentum % | 15.41 | |||||
12-1 Month Momentum % | 178.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 21.18 | |||||
Quick Ratio | 21.18 | |||||
Cash Ratio | 20.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | -10.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -54.73 | |||||
ROA % | -42.99 | |||||
ROIC % | -1474.72 | |||||
3-Year ROIIC % | -454.27 | |||||
ROC (Joel Greenblatt) % | -10259.17 | |||||
ROCE % | -40.67 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 10.05 | |||||
Price-to-Tangible-Book | 10.04 | |||||
EV-to-EBIT | -35.68 | |||||
EV-to-Forward-EBIT | -17.61 | |||||
EV-to-EBITDA | -35.68 | |||||
EV-to-Forward-Revenue | 71.63 | |||||
EV-to-FCF | -52.87 | |||||
| Price-to-Net-Current-Asset-Value | 10.06 | |||||
| Price-to-Net-Cash | 10.18 | |||||
Earnings Yield (Greenblatt) % | -2.8 | |||||
FCF Yield % | -1.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PVLA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Palvella Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.83 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 92.41 | ||
| 14-Day RSI | 51.32 | ||
| 14-Day ATR ($) | 7.746612 | ||
| 20-Day SMA ($) | 151.361 | ||
| 12-1 Month Momentum % | 178.2 | ||
| 52-Week Range ($) | 53.3 - 161.38 | ||
| Shares Outstanding (Mil) | 14.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Palvella Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Palvella Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-11 08:30 | In 63 days | ||
| Third quarter earnings results for 2026 | 2026-11-11 | In 62 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-15 12:00 | In 6 days | ||
| Guidance call for 2026 | 2026-09-09 13:35 | 152.28 (-0.74%) | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-12 15:30 | 154.30 (+0.16%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:30 | 140.78 (+1.97%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 140.78 (+1.97%) | ||
| General meeting for 2026 | 2026-06-10 11:00 | 104.37 (-1.72%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:40 | 105.25 (-5.01%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 130.17 (+0.56%) |
Show
Entries
Palvella Therapeutics Inc Frequently Asked Questions
What is Palvella Therapeutics Inc(PVLA)'s stock price today?
The current price of PVLA is $151.25. The 52 week high of PVLA is $161.38 and 52 week low is $53.30.
When is next earnings date of Palvella Therapeutics Inc(PVLA)?
The next earnings date of Palvella Therapeutics Inc(PVLA) is 2026-11-11 Est..
Does Palvella Therapeutics Inc(PVLA) pay dividends? If so, how much?
Palvella Therapeutics Inc(PVLA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Palvella Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers